| Biomarker ID | 1597 |
| PMID | 26254378 |
| Year | 2015 |
| Biomarker | Prostate Health Index (phi) |
| Biomarker Basis | Concentration Based (μg/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [BPH: 35.1 (13.1-155.6); PCa:61.6 (17.0-231.8)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 150 patients with Benign Prostatic Hyperplasia and 113 with Prostate cancer were selected for the study |
| Senstivity | Cut off 30: 30%; Cut off 37: 53%; Cut off 40: 63%; |
| Specificity | Cut off 30: 98%; Cut off 37: 90%; Cut off 40: 84%; |
| AUC | 0.79451 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Chemiluminescence |
| Clinical | No |
| Remarks | PHI = [(p2PSA / fPSA) / √tPSA] |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |